AU3011299A - Combination therapy for the treatment of benign prostatic hyperplasia - Google Patents
Combination therapy for the treatment of benign prostatic hyperplasiaInfo
- Publication number
- AU3011299A AU3011299A AU30112/99A AU3011299A AU3011299A AU 3011299 A AU3011299 A AU 3011299A AU 30112/99 A AU30112/99 A AU 30112/99A AU 3011299 A AU3011299 A AU 3011299A AU 3011299 A AU3011299 A AU 3011299A
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- combination therapy
- benign prostatic
- prostatic hyperplasia
- hyperplasia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7904198P | 1998-03-23 | 1998-03-23 | |
US60079041 | 1998-03-23 | ||
GBGB9810895.4A GB9810895D0 (en) | 1998-05-20 | 1998-05-20 | Combination therapy for the treatment of benign prostatic hyperplasia |
GB9810895 | 1998-05-20 | ||
PCT/US1999/006014 WO1999048530A1 (en) | 1998-03-23 | 1999-03-19 | Combination therapy for the treatment of benign prostatic hyperplasia |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3011299A true AU3011299A (en) | 1999-10-18 |
Family
ID=26313720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU30112/99A Abandoned AU3011299A (en) | 1998-03-23 | 1999-03-19 | Combination therapy for the treatment of benign prostatic hyperplasia |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3011299A (en) |
WO (1) | WO1999048530A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6268369B1 (en) | 1994-11-16 | 2001-07-31 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
KR970706823A (en) | 1994-11-16 | 1997-12-01 | 멀닉스 캐슬린 피. | DIHYDROPYRIMIDINES AND USES THEREOF (DIHYDROPYRIMIDINES AND USES THEREOF) |
US6228861B1 (en) | 1995-11-16 | 2001-05-08 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6172066B1 (en) | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6245773B1 (en) | 1996-05-16 | 2001-06-12 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
US6228870B1 (en) | 1998-11-10 | 2001-05-08 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1a adrenoceptor antagonists |
US6319932B1 (en) | 1998-11-10 | 2001-11-20 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1A adrenoceptor antagonists |
AU1345900A (en) * | 1998-11-10 | 2000-05-29 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1a adrenoceptor antagonists |
AU1345800A (en) * | 1998-11-10 | 2000-05-29 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1a adrenoceptor antagonists |
AU1346000A (en) * | 1998-11-10 | 2000-05-29 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1a adrenoceptor antagonists |
GB2344821A (en) | 1998-12-17 | 2000-06-21 | Merck & Co Inc | Crystalline pharmaceutically acceptable salt of an oxazolidinone derivative |
WO2000037026A1 (en) * | 1998-12-23 | 2000-06-29 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6274585B1 (en) * | 1998-12-23 | 2001-08-14 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6680323B2 (en) | 1998-12-23 | 2004-01-20 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
NL1015313C2 (en) | 2000-05-26 | 2001-11-27 | Dsm Nv | Process for the preparation of enantiomerically enriched esters and alcohols. |
US6720324B2 (en) | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
JP2001288115A (en) * | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | Remedy for lower urinary tract symptom |
EP1293198B1 (en) * | 2001-09-14 | 2005-02-09 | Schwarz Pharma Ag | Device for transdermal administration for the treatment of urinary tract disorders |
GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
UA78854C2 (en) * | 2002-09-06 | 2007-04-25 | Kissei Pharmaceutical | Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same |
US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
CA2557758C (en) | 2004-03-05 | 2013-09-10 | Kissei Pharmaceutical Co., Ltd. | Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996022978A1 (en) * | 1995-01-27 | 1996-08-01 | Rhone Poulenc Rorer Limited | Substituted phenyl compounds as endothelin antagonists |
DE69422742T2 (en) * | 1993-03-19 | 2000-08-17 | Merck & Co., Inc. | Phenoxyphenylacetic acid derivatives |
ATE199151T1 (en) * | 1993-08-18 | 2001-02-15 | Banyu Pharma Co Ltd | CONDENSED HETEROAROMATIC CYCLOPENT DERIVATIVES WITH ENDOTHELIN ANTAGONISTIC ACTIVITY |
JPH10503779A (en) * | 1994-08-08 | 1998-04-07 | メルク エンド カンパニー インコーポレーテッド | Phenoxyphenylacetic acid derivative |
US5559135A (en) * | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
KR970706823A (en) * | 1994-11-16 | 1997-12-01 | 멀닉스 캐슬린 피. | DIHYDROPYRIMIDINES AND USES THEREOF (DIHYDROPYRIMIDINES AND USES THEREOF) |
US5597823A (en) * | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
-
1999
- 1999-03-19 WO PCT/US1999/006014 patent/WO1999048530A1/en active Application Filing
- 1999-03-19 AU AU30112/99A patent/AU3011299A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1999048530A1 (en) | 1999-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3011299A (en) | Combination therapy for the treatment of benign prostatic hyperplasia | |
AU2212299A (en) | Compositions and methods for the treatment of tumor | |
SI0968208T1 (en) | Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia | |
AU6393896A (en) | Method for treating benign prostatic hyperplasia with thermal therapy | |
IL189132A0 (en) | Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer | |
AU3891299A (en) | Combination therapy for treatment of depression | |
AU1316000A (en) | Compositions and methods for treating benign prostatic hyperplasia using tocotrienols | |
AU2235395A (en) | Biological markers of benign prostate hyperplasia | |
IL136960A0 (en) | Combination therapy for the treatment of migraine | |
AU6062900A (en) | Substituted indole compounds and their use for the treatment of cancer | |
ZA983968B (en) | Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia. | |
HUP0101947A3 (en) | Combination for the treatment of tumors | |
AU7105498A (en) | Combination therapy for the prevention and treatment of osteoporosis | |
ZA982819B (en) | Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators. | |
HK1030776A1 (en) | Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia | |
AU3896899A (en) | Compositions for the treatment of tumors, and uses thereof | |
AU2001285156A1 (en) | Combination therapy for the treatment of migraine | |
AU9128998A (en) | Composition and method for the treatment of benign prostatic hyperplasia and prostatitis | |
AU1940800A (en) | Combination therapy for the treatment of sepsis | |
IL136025A0 (en) | Combination therapy for the treatment of migraine | |
GB9810895D0 (en) | Combination therapy for the treatment of benign prostatic hyperplasia | |
AU2390700A (en) | Polypeptidic compositions and methods for the treatment of tumors | |
AU1036701A (en) | Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia | |
ZA991319B (en) | Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia. | |
IL136024A0 (en) | Combination therapy for the treatment of migraine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |